Speakers: Jeff Wallin (Genentech), Gary Starling (Merck), Juan Jaen (ex Flexus BioScience), Stephen Shuttleworth (Karus Therapeutics), Sanjay Khare (ImmunGene), Thomas Schall (ChemoCentryx), Eric Wakshull (Genentech), Cheni Kwok (Linear Dreams)
Organizers: Cheni Kwok, Surinder Kaur, Shichang Miao, Wenfeng Xu
Date: 2015-10-01
Time: 9:00-17:00 Pacific Time
Registration fee: (USD): Regular: $195; For vendor-show rep: $35; For unemployed & students: $30; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Crowne Plaza Hotel, 1221 Chess Dr., Foster City, CA 94404
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:2015-10-09  (it will close sooner if the seating cap is reached)

About the Topic

The last few years have seen some transformative developments in cancer treatment through immunotherapy. This minisymposium aims to provide a comprehensive overview of the exciting field of cancer Immunotherapy from the latest biologic insights to the immuno-oncology pathways, key learnings in translating research findings to the clinic, latest clinical data on approved immuno-oncology agents and emerging agents in the pipeline as well as trends in business partnerships.

Agenda:

9:00am - 9:15am: PBSS Overview & Welcome (Shichang Miao, PhD, PBSS President (Executive Director, ChemoCentryx); Cheni Kwok PhD, CLP (Managing Partner, Linear Dreams))

9:15am - 9:55am: Translating targets to therapeutics - an introductory overview of cancer immunotherapy and biomarker strategy (Jeff Wallin, PhD, Senior Scientist / Group Leader, Development Science, Genentech)

9:55am - 10:35am: Maximizing the Benefit of Anti-PD1 Therapy (Gary Starling PhD, Associate Vice President, Biologics Discovery Operations, Merck)

10:35am - 10:45am: Major Sponsor Presentation (Eurofin)

11:00am - 11:40am: Finding Gold in the Goldilocks Zone, the Flexus Story of Drug Discovery in Immuno-Oncology (Juan Jaen, PhD, Former President & Head R&D, Flexus BioScience)

11:40am - 12:20pm: Unlocking Immuno-Oncology Therapeutic Potential of PI3 Kinase and HDAC (Stephen Shuttleworth, PhD, FRSC, Chief Scientific Officer, Karus Therapeutics)

1:20pm - 2:00pm: Multipronged Approach with Immunotherapy and Direct Targeted Killing to Say Bye2Cancer (Sanjay Khare, PhD, CEO, ImmuneGene)

2:00pm – 2:40pm: Regulating the Chemokines/Chemokine Receptors Axis for Immuno Oncology (Thomas Schall, PhD, CEO, ChemoCentryx)

2:40pm – 2:50pm Major Sponsor Presentation (Charles River Laboratories)

3:05pm – 3:35pm: PK/Bioanalytical Strategies and Challenges for Large Molecule Cancer Immunotherapy Drug Development (Eric Wakshull, PhD, Senior Scientist / Group Leader, Development Sciences, Genentech)

3:35pm- 4:05pm: Chasing Gold: Cancer Immunotherapy Deals & Business Outlook (Cheni Kwok PhD CLP, Managing Partner, Linear Dreams)

4:20pm – 5:00pm: Panel Discussion and Q&A